Known targets — ChEMBL curated mechanism
ABCC8ACEADORA1ADORA2AADORA2BADORA3ALDH5A1ALOX5ALOX5APATP4AATP4BBRAFCA1CA12CA2CA4CYSLTR1DHFRDPEP1EDNRAEDNRBESR2F10FDPSFGF1GABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTGNRHRGSC1HMGCRIMPDH1IMPDH2KCNJ11LY96NOD2NR3C1NS3NS4ANS5bP2RY1P2RY12P2RY2P2RY4P2RY6PBP2XPDE3APDE3BPDE4APDE4BPDE4CPDE4DPDK1PDK2PDK3PDK4PPARGPPATPTGIRPTGS1PTGS2RAF1RYR1RYR3SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASERPINC1SLC12A1SLC12A3SYKTHRATHRBTLR3TLR4TLR9TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYMSVKORC1XDHblablaIMP-1blaOXA-33blaOXA-58blaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAfolPfolP1ftsIfusAgaggyrAgyrBmecAmrcAmrcBmrdApbp1apbp1bpbp2pbp2apbp2bpbp3pbp4pbpApbpBpbpCpbpFpolponBrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpoArpoBrpoCrpoZrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 known ✓ | O43570 | 2/20 | 0.35 |
| ▸ | CA1 known ✓ | P00915 | 2/20 | 0.35 |
| ▸ | CA2 known ✓ | P00918 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | CA9 | Q16790 | 2/20 | 0.35 |
| ▸ | CTSK | P43235 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | JAK2 | O60674 | 2/20 | 0.31 |
| ▸ | SMG1 | Q96Q15 | 1/20 | 0.31 |
| ▸ | KDM1A | O60341 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29834643 | 1.00 | ALDH1A1 (0.35) | ALDH1A1ALOX15TSHRCA12CA1 | |
| SCHEMBL14893918 | 0.91 | ALDH1A1 (0.35) | ALDH1A1ALOX15TSHRCA12CA1 | |
| SCHEMBL9929264 | 0.76 | ALDH1A1 (0.36) | ALDH1A1ALOX15TSHRCA12CA1 | |
| SCHEMBL5669473 | 0.65 | GRM4 (0.32) | ALDH1A1NPC1RAB9A | |
| SCHEMBL9805980 | 0.63 | DAPK1 (0.30) | ALDH1A1NPC1RAB9A | |
| SCHEMBL9624630 | 0.62 | CA12 (0.50) | ALDH1A1CA12CA1CA2CA9 | |
| SCHEMBL10486391 | 0.60 | PRKDC (0.42) | ALDH1A1ALOX15TSHRMAPTKDM1A | |
| SCHEMBL2729083 | 0.60 | CA12 (0.57) | ALDH1A1CA12CA1CA2CA9 | |
| SCHEMBL9929254 | 0.60 | CA12 (0.39) | ALDH1A1ALOX15TSHRCA12CA1 | |
| SCHEMBL10440183 | 0.60 | PRKDC (0.41) | ALDH1A1ALOX15TSHRMAPTKDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 104 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250313817-A1 | POLYPEPTIDES | NOVOZYMES A/S (DK) | 2025-10-09 | — | — | US | disclosed |
| US-20250171717-A1 | DETERGENT COMPOSITIONS AND USES THEREOF | NOVOZYMES A/S (DK) | 2025-05-29 | — | — | US | disclosed |
| US-12241045-B2 | Detergent compositions and uses thereof | NOVOZYMES A/S (DK) | 2025-03-04 | — | — | US | disclosed |
| US-20250051744-A1 | POLYPEPTIDES | NOVOZYMES A/S (DK) | 2025-02-13 | — | — | US | disclosed |
| US-20240228913-A1 | ENZYME COMPOSITIONS AND USES THEREOF | NOVOZYMES A/S (DK) | 2024-07-11 | — | — | US | disclosed |
| US-20240209335-A1 | Cleaning Compositions Comprising Enzymes | NOVOZYMES A/S (DK) | 2024-06-27 | — | — | US | disclosed |
| US-11959106-B2 | Cleaning compositions comprising enzymes | NOVOZYMES A/S (DK) | 2024-04-16 | — | — | US | disclosed |
| US-20230340367-A1 | Detergent Compositions and Uses Thereof | NOVOZYMES A/S (DK) | 2023-10-26 | — | — | US | disclosed |
| US-20230287306-A1 | Cleaning Composition | NOVOZYMES A/S (DK) | 2023-09-14 | — | — | US | disclosed |
| US-11680231-B2 | Detergent compositions and uses thereof | NOVOZYMES A/S (DK) | 2023-06-20 | — | — | US | disclosed |
| WO-2013062885-A1 | PERHYDROLASE VARIANT PROVIDING IMPROVED SPECIFIC ACTIVITY | E.I. DUPONT DE NEMOURS AND COMPANY (US) | 2013-05-02 | — | — | WO | disclosed |
| US-20130102670-A1 | PERHYDROLASE VARIANT PROVIDING IMPROVED SPECIFIC ACTIVITY | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2013-04-25 | — | — | US | disclosed |
| US-20130102664-A1 | PERHYDROLASE VARIANT PROVIDING IMPROVED SPECIFIC ACTIVITY | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2013-04-25 | — | — | US | disclosed |
| US-20130102666-A1 | PERHYDROLASE VARIANT PROVIDING IMPROVED SPECIFIC ACTIVITY | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2013-04-25 | — | — | US | disclosed |
| US-20130102671-A1 | PERHYDROLASE VARIANT PROVIDING IMPROVED SPECIFIC ACTIVITY | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2013-04-25 | — | — | US | disclosed |
| US-20130102667-A1 | PERHYDROLASE VARIANT PROVIDING IMPROVED SPECIFIC ACTIVITY | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2013-04-25 | — | — | US | disclosed |
| US-20130102669-A1 | PERHYDROLASE VARIANT PROVIDING IMPROVED SPECIFIC ACTIVITY | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2013-04-25 | — | — | US | disclosed |
| US-20130102665-A1 | PERHYDROLASE VARIANT PROVIDING IMPROVED SPECIFIC ACTIVITY | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2013-04-25 | — | — | US | disclosed |
| US-20130102672-A1 | PERHYDROLASE VARIANT PROVIDING IMPROVED SPECIFIC ACTIVITY | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2013-04-25 | — | — | US | disclosed |
| US-20130102668-A1 | PERHYDROLASE VARIANT PROVIDING IMPROVED SPECIFIC ACTIVITY | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2013-04-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130102667-A1 | PERHYDROLASE VARIANT PROVIDING IMPROVED SPECIFIC ACTIVITY | HPD, HOGA1, APEH | CA12 1783/4885CA1 939/4885CA2 484/4885 |
| US-20130102665-A1 | PERHYDROLASE VARIANT PROVIDING IMPROVED SPECIFIC ACTIVITY | HPD, HOGA1, APEH | CA12 1783/4885CA1 939/4885CA2 484/4885 |
| US-20130102666-A1 | PERHYDROLASE VARIANT PROVIDING IMPROVED SPECIFIC ACTIVITY | HPD, HOGA1, APEH | CA12 1783/4885CA1 939/4885CA2 484/4885 |
| US-20130102669-A1 | PERHYDROLASE VARIANT PROVIDING IMPROVED SPECIFIC ACTIVITY | HPD, HOGA1, APEH | CA12 1783/4885CA1 939/4885CA2 484/4885 |
| US-20130102671-A1 | PERHYDROLASE VARIANT PROVIDING IMPROVED SPECIFIC ACTIVITY | HPD, HOGA1, APEH | CA12 1783/4885CA1 939/4885CA2 484/4885 |
| US-20130102664-A1 | PERHYDROLASE VARIANT PROVIDING IMPROVED SPECIFIC ACTIVITY | HPD, HOGA1, APEH | CA12 1783/4885CA1 939/4885CA2 484/4885 |
| US-20130102670-A1 | PERHYDROLASE VARIANT PROVIDING IMPROVED SPECIFIC ACTIVITY | HPD, HOGA1, APEH | CA12 1783/4885CA1 939/4885CA2 484/4885 |
| US-20130102668-A1 | PERHYDROLASE VARIANT PROVIDING IMPROVED SPECIFIC ACTIVITY | HPD, HOGA1, APEH | CA12 1783/4885CA1 939/4885CA2 484/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.